

**Statements of Support for the Discounted Drugs for Clinical Trials Act, the
Pharmaceutical Research and Transparency Act, and the Generic Substitution Non-
Interference Act**

Peter Maybarduk, Director of Public Citizen’s Access to Medicines Program: “Big Pharma is a many-tentacled beast; each arm probing opportunity to choke generic competition and limit access to affordable medicine. These bills would sever three tentacles – interference with generic substitution at the pharmacy, purposefully opaque clinical trial costs and inaccessible product samples – helping researchers and pharmacists shed light on true costs, bring competition to market and provide affordable generics to patients. We thank Chairwoman Maloney, Reps. Welch, Schakowsky and Cicilline and Sens. Stabenow and Smith for their leadership. Public Citizen endorses and calls for the swift passage of the Discounted Drugs for Clinical Trials Act, the Pharmaceutical Research and Transparency Act and the Generic Substitution Non-Interference Act.”

Margarida Jorge, Campaign Director at Lower Drug Prices Now: "This package of bills is an important step towards holding Big Pharma accountable and providing much needed relief for patients struggling to afford the high price of prescription medicines. Paired with comprehensive prescription drug reform, including the power for Medicare to negotiate, Congress can finally rein in the pharmaceutical corporations monopoly power to price gouge consumers, patients and businesses in order to inflate their profits at the expense of our health. We applaud Chairwoman Maloney and the Democrats on the Committee for holding important hearings to expose the worst business practices of this industry and for advancing these critical bills.”

Patricia Kelmar, Director of Health Care Campaigns at U.S. PIRG: “Competition from lower-priced generic medicines that offer patients the same therapeutic treatment forces drugmakers to bring down their brand-name prices. Unfortunately, that trend has slowed because of too many barriers to competition in the pharmaceutical industry. Chairwoman Maloney and the House Oversight Committee did an excellent job of identifying ways our current system stifles a competitive market. This package of three important bills will increase cost transparency for innovation, increase access to brand medications for generic competitors to develop lower cost alternatives, and support patients' access to generic and biosimilar drugs at the pharmacy. Drug prices have been increasing year over year. These bills are a vital start to pulling down the obstacles to competition and bringing about needed reforms. Americans deserve greater transparency and improved access to lower-cost medications.”

Alex Lawson, Executive Director of Social Security Works: "The American people are beyond fed up with high drug prices. Pharmaceutical corporations rake in billions of dollars with every conceivable rip-off and con you can imagine. That is why we enthusiastically endorse this trio of bills from Chairwoman Maloney and the House Oversight Committee. These bills will bring relief to seniors and working families by targeting pharmaceutical scams and requiring transparency."